Head-to-head · WeighScore
Ivy Rx vs Ro
The verdict
Ro takes it — 80.2/100 to 66.5/100.
Ro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A heavyweight platform with brand-name access — but opaque compounded pricing drags its score.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ivy Rx | Ro |
|---|---|---|
| WeighScore | 66.5/100 | 80.2/100 |
| Grade | C | B− |
| Scorecard rank | #190 | #38 |
| Semaglutide | $175/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | $275/mo (starting dose, compounded) | Not disclosed |
| Coverage | All 50 states | Multi-state |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #190 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- Limited public information on program details
Graded #38 · B−
Strengths
- Brand-name access + insurance support
- Oral options
- Well-funded platform
Where it loses points
- Does not disclose compounded pricing up front
- Premium positioning
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.